<DOC>
	<DOCNO>NCT01763450</DOCNO>
	<brief_summary>A multi-center , non-random , open study , observe efficacy safety bevacizumab plus Oxaliplatin base multidrug chemotherapy conversion therapy patient previously untreated unresectable liver metastasis colorectal cancer .</brief_summary>
	<brief_title>Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES：To assess objective response rate ( ORR ) （8 week chemotherapy） SECONDARY OBJECTIVES： 1 . To assess R0 resection rate liver metastases（8 week chemotherapy、every three month follow-up 1 time R0 postoperative 1-2 years、Every six month follow-up 1 time R0 postoperative 2-5 years） 2 . To assess incidence adverse event level 3-4 （Bleeding、Gastrointestinal Perforation、Anastomotic Fistula、Hypertension、Wound Healing Delay）（8 week chemotherapy）</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Written inform consent form 2. histologically cytologically confirm Colorectal Adenocarcinoma 3 . Age≥18 ≤80 year old 4 . Primary colorectal cancer liver metastases，Liver lesion determine unresectable multidisciplinary team ( MDT ) （primary lesion surgically removed） 5 . Simultaneity heterochrony metastases 6 . Colorectal cancer lesion anal edge least 8 cm 7 . Within 6 month receive chemotherapy , include target therapy 8 . One measurable lesion , conventional Computed Tomography ( CT ) scan measurement diameter least 20 mm [ Response Evaluation Criteria In Solid Tumors ( RECIST ) standard ] 9 . Eastern Collaborative Oncology Group ( ECOG ) 0 1 10 . Expected lifetime least 12 week 11 . Screening within 7 days， ability bone marrow , liver kidney function reserve enough；Absolute neutrophil count（ANC）≥1.5x109/L ; hemoglobin≥9.0g/dl ; platelet count≥80 x109/L ; Total Bilirubin ( TBil ) ≤1.5 x upper level normal range ( ULN ) ; Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) ≤2.5 x ULN ( Patients hepatic metastasis≤5x ULN ) ; alkaline phosphatase≤4 x ULN ; serum creatinine≤1.5 x ULN ; 12 . Women reproductive age take effective contraceptive measure ; 1 . Arrhythmia require medication（except β receptor block pharmacon digoxigenin），symptomatic coronary artery disease myocardial ischemia [ myocardial infarction ( ≤6months enrollment ) ] ，congestive heart failure [ ≥New York Heart Association ( NYHA ) 2 ] ; 2 . History HIV infection , Chronic hepatitis B hepatitis C active phase ( high copy virus DNA ) ; 3 . Other activate serious infection [ &gt; National Cancer InstituteCommon Toxicity Criteria ( NCICTC ) 3.0 ] ; 4 . Any extrahepatic metastasis ; 5 . Seizures require medication ( steroids antiepileptic therapy ) ; 6 . Other malignancy past 5 year ( except curatively treat basal cell carcinoma skin and/or situ carcinoma cervix ) ; 7 . Chronic inflammatory bowel disease , intestinal obstruction ; 8 . Drug abuse medicine , psychology social condition may interfere patient participate research result evaluation influence ; 9 . Known suspected allergy investigational drug study ; 10 . Any unstable condition likely endanger patient safety compliance situation ; 11 . Pregnant lactate woman use refuse use effective non hormonal mean contraception ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>conversion therapy</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>objective response rate</keyword>
</DOC>